These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Carneiro BA; Collier KA; Nagy RJ; Pamarthy S; Sagar V; Fairclough S; Odegaard J; Lanman RB; Costa R; Taxter T; Kuzel TM; Fan A; Chae YK; Cristofanilli M; Hussain MH; Abdulkadir SA; Giles FJ JCO Precis Oncol; 2018; 2():. PubMed ID: 31501807 [TBL] [Abstract][Full Text] [Related]
6. Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives. Vande Perre P; Toledano D; Corsini C; Escriba E; Laporte M; Bertet H; Yauy K; Toledano A; Galibert V; Baudry K; Clotet L; Million E; Picot MC; Geneviève D; Pujol P Mol Genet Genomic Med; 2018 Nov; 6(6):957-965. PubMed ID: 30308700 [TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b. Mogilyansky E; Clark P; Quann K; Zhou H; Londin E; Jing Y; Rigoutsos I Front Genet; 2016; 7():143. PubMed ID: 27630665 [TBL] [Abstract][Full Text] [Related]
8. Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. Cava C; Bertoli G; Castiglioni I BMC Syst Biol; 2015 Sep; 9():62. PubMed ID: 26391647 [TBL] [Abstract][Full Text] [Related]
9. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678 [TBL] [Abstract][Full Text] [Related]
10. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Krajewska M; Fehrmann RS; Schoonen PM; Labib S; de Vries EG; Franke L; van Vugt MA Oncogene; 2015 Jun; 34(26):3474-81. PubMed ID: 25174396 [TBL] [Abstract][Full Text] [Related]
11. Targeting signaling pathways in epithelial ovarian cancer. Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885 [TBL] [Abstract][Full Text] [Related]
13. A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. Purnomosari D; Paramita DK; Aryandono T; Pals G; van Diest PJ J Clin Pathol; 2005 May; 58(5):493-9. PubMed ID: 15858120 [TBL] [Abstract][Full Text] [Related]
14. The D13S171 marker, misannotated to BRCA2, links the AS3 gene to various cancers. Geck P; Sonnenschein C; Soto AM Am J Hum Genet; 2001 Aug; 69(2):461-3. PubMed ID: 11452363 [No Abstract] [Full Text] [Related]
15. Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Geck P; Maffini MV; Szelei J; Sonnenschein C; Soto AM Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10185-90. PubMed ID: 10963680 [TBL] [Abstract][Full Text] [Related]
16. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777 [TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 proteins: roles in health and disease. Duncan JA; Reeves JR; Cooke TG Mol Pathol; 1998 Oct; 51(5):237-47. PubMed ID: 10193517 [TBL] [Abstract][Full Text] [Related]
18. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. Arason A; Jonasdottir A; Barkardottir RB; Bergthorsson JT; Teare MD; Easton DF; Egilsson V J Med Genet; 1998 Jun; 35(6):446-9. PubMed ID: 9643283 [TBL] [Abstract][Full Text] [Related]
19. Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes. Moerland E; Breuning MH; Cornelisse CJ; Cleton-Jansen AM Br J Cancer; 1997; 76(12):1550-3. PubMed ID: 9413939 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. Bièche I; Noguès C; Rivoilan S; Khodja A; Latil A; Lidereau R Br J Cancer; 1997; 76(11):1416-8. PubMed ID: 9400936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]